ASCO 2022 | Prevalence of DDR alterations in patients with mHSPC enrolled in ARCHES

Arun Azad, MBBS, PhD, FRACP, Peter MacCallum Cancer Centre, Victoria, Australia, provides an overview of a post hoc analysis of the ARCHES study (NCT02677896), where patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide and androgen deprivation therapy (ADT) had a reduced risk of radiographic progression or death and improved overall survival versus placebo and ADT. This post hoc analysis found a lower prevalence of DNA damage repair (DDR) alterations in patients with mHSPC in ARCHES, compared with the 7–12% previously reported in patients with metastatic castration-resistant prostate cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.